ArticleInternational journal of retina and vitreous2025
Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidence and Clinical Course of Intraocular Inflammation Following Pharmacy-Compounded Intravitreal Aflibercept 8mg for Neovascular AMD: A Real-World Cohort Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyze the incidence, and clinical characteristics of intraocular inflammation (IOI) associated with faricimab in a tertiary center in Austria.
methodsA retrospective analysis of IOI cases following intravitreal faricimab injections in the Kepler University Hospital Linz, Austria. Clinical data was analyzed from January 2023, until March 10th 2025. Clinical and optical coherence tomography (OCT) findings including vitreous changes via mean vitreous grey value (MVGV) were evaluated.
resultsA total of 7333 intravitreal injections of faricimab for a total of 1137 patients were applied during the observation period. We identified 11 eyes with an IOI after faricimab injection with a mean follow up of 22.5 days (range 3–42 days) which corresponds to an incidence of IOI of 0.15% per injection. Quantitative OCT analysis showed a significant rise in mean vitreous gray value during IOI (p = 0.002), which returned to baseline after treatment (p = 0.63). A significant, fully reversible increase in vitreous haze during IOI episodes was shown. Clinical findings included both anterior and posterior segment inflammation in the absence of pain or occlusive vasculitis.
conclusionThe results suggest a low incidence of IOI after faricimab injections, comparable to registration trials. MVGV analysis via OCT proved to be sensitive and reproducible. All cases resolved with topical treatment. Intravitreal therapy with faricimab has shown to have a low risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.